In a recent data analysis, it has been observed that Eli Lilly’s Mounjaro outperforms Novo Nordisk’s popular obesity drug in terms of both the amount and speed of weight loss among overweight or obese adults.
The study, based on an examination of health records and comprehensive data, indicates that within the first year of treatment, 42.3% of individuals administered tirzepatide, the active component in Mounjaro and Zepbound, successfully shed a minimum of 15% of their body weight. In stark contrast, only 19.3% of patients taking semaglutide, the primary ingredient in Novo’s Wegovy and Ozempic, achieved a comparable weight loss, as reported in the study published on medRxiv, pending peer review.
Displayed in pharmacies across the country, the pharmaceutical products Ozempic and Mounjaro, developed by Novo Nordisk and Eli Lilly respectively, have become noteworthy contenders in the treatment of type 2 diabetes. The research underscores Mounjaro’s efficacy, signaling a potential shift in preference within the realm of weight loss medications. This development is expected to stimulate further discussions within the medical community about the comparative advantages of these two leading drugs.